Registered title, quoted from ClinicalTrials.gov
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fujian Cancer Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteFujian Provincial Hospital福建省立医院FuzhouHospital page
- Study siteSecond Affiliated Hospital of Fujian Medical University福建医科大学附属第二医院QuanzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07880600, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: women only
Registered eligibility fields
Histologically confirmed invasive triple-negative breast cancer; patients with ER/PR 1%-10% positive and HER2-negative status are also eligible given their biological features resembling triple-negative breast cancer.
Inclusion criterion 2
Availability of both MRI and pathological biopsy materials; standardized breast DCE-MRI examination and pathological biopsy completed prior to neoadjuvant chemotherapy, with image quality satisfying requirements for model analysis.
Inclusion criterion 4
Post-operative pathology available to assess neoadjuvant chemotherapy response (pCR or non-pCR).
Inclusion criterion 6
Clinical stage T2-3N0-3M0 or T1N1-3M0 according to AJCC 8th edition, with potential indication for neoadjuvant chemotherapy.
Inclusion criterion 3
Missing required clinical information, MRI images, or pathological biopsy specimens for analysis.
Exclusion criterion 9
Inflammatory breast cancer or distant metastatic disease (M1).
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07880600, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female patients aged ≥ 18 years.
- Histologically confirmed invasive triple-negative breast cancer; patients with ER/PR 1%-10% positive and HER2-negative status are also eligible given their biological features resembling triple-negative breast cancer.
- Clinical stage T2-3N0-3M0 or T1N1-3M0 according to AJCC 8th edition, with potential indication for neoadjuvant chemotherapy.
- Availability of both MRI and pathological biopsy materials; standardized breast DCE-MRI examination and pathological biopsy completed prior to neoadjuvant chemotherapy, with image quality satisfying requirements for model analysis.
- Patients planned to receive standard neoadjuvant chemotherapy followed by surgical treatment. Patients who are undergoing standard neoadjuvant chemotherapy or have completed neoadjuvant chemotherapy awaiting surgery are also eligible.
- Post-operative pathology available to assess neoadjuvant chemotherapy response (pCR or non-pCR).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1; adequate function of major organs to tolerate planned therapy.
- Voluntary participation and provision of written informed consent.
Exclusion Criteria:
- Prior systemic anti-tumor therapy for breast cancer other than neoadjuvant chemotherapy.
- Inflammatory breast cancer or distant metastatic disease (M1).
- Concurrent active malignancy during neoadjuvant chemotherapy or surgical period.
- History of autoimmune diseases, such as systemic lupus erythematosus, acanthosis and other related disorders.
- Documented history of neurological or psychiatric disorders, including epilepsy, dementia, etc.
- Contraindications to MRI or unacceptable image quality for analysis.
- No definitive surgery performed or incomplete postoperative pathological reports.
- Severe comorbidities that preclude chemotherapy or surgical intervention.
- Missing required clinical information, MRI images, or pathological biopsy specimens for analysis.
- Other conditions rendering the subject inappropriate for enrollment, in the investigator's judgment.
Quoted from ClinicalTrials.gov, NCT07880600, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07880600, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.